Multicenter Randomised Double-blind Study to Compare HR3 or Placebo in Combination With Cisplatin-navelbine for Patients With Cervical Carcinoma, Followed in Case of Progression by a Second Line
Status: Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 22 Mar 2019
Price : $35 *
At a glance
- Drugs Nimotuzumab (Primary) ; Cisplatin; Vinorelbine
- Indications Cervical cancer
- Focus Therapeutic Use
- Sponsors ELKendi
- 18 Mar 2019 Planned End Date changed from 1 Dec 2019 to 1 Dec 2021.
- 18 Mar 2019 Planned primary completion date changed from 1 Dec 2019 to 1 Jan 2020.
- 18 Mar 2019 Status changed from recruiting to active, no longer recruiting.